Pharmacokinetics
Pharmacokinetic profiles of evogliptin and pioglitazone after EVO+PIO were similar with those after evogliptin or pioglitazone alone, respectively. The mean plasma concentration-time profiles of evogliptin with its metabolites (M6, M7) after EVO and EVO+PIO, and pioglitazone with its metabolites (M3, M4) after PIO and EVO+PIO were comparable (Figure 2 and Supplementary figure 1).
GMR (90% CI) of EVO+PIO to EVO and for Cmax,ss and AUCτ,ss of evogliptin were 1.01 (0.97 – 1.05) and 1.01 (0.98 - 1.04), contained within conventional bioequivalence range[17] of 0.80 – 1.25 (Table 1). The corresponding values of EVO+PIO to PIO and its 90% CI for Cmax,ss and AUCτ,ss of pioglitazone were 1.07 (0.99 – 1.17) and 1.08 (0.99 – 1.17), contained within conventional bioequivalence range as well (Table 2).